Blue Cross Blue Shield OK Drug List Coverage

inv-01: Coverage criteria and utilization management

Covered when the following formulary and utilization-management conditions are met:

General coverage framework: Drug is covered if it is listed on the BCBSOK Drug List and is used consistent with FDA‑approved labeling or recognized evidence‑based clinical practice guidelines.

See Coverage considerations and Exception Process for scope and limits.

Exclusions that affect coverage: Drugs not shown on the Drug List, non‑FDA‑approved drugs, repackaged medications, and certain compounded or over‑the‑counter equivalent products may be excluded from coverage.

Non‑listed or non‑FDA approved drugs are not covered per plan terms.

Utilization management controls: Coverage may require prior authorization (PA) when the drug line shows 'PA'; step therapy (ST) when 'ST' is shown; and/or adherence to dispensing/quantity limits (QL) when a 'QL' is indicated.

PA/ST/QL flags are shown in the Special Requirements column next to individual products.

Exception and review process: Providers or members may request a Drug List, step‑therapy, or coverage exception; standard requests will be decided within 3 business days and expedited (urgent) requests within 24 hours.

See Exception Process for submission and timelines.

inv-02: Formulary coverage with per-product requirements

Coverage of each product is conditional on the drug tier and any per‑product requirements shown on the drug line:

Per‑product coverage rule: Drug coverage is governed by the listed Drug Tier and the Requirements/Limits field — examples include PA (prior authorization), QL (quantity/dispensing limits), and SP (specialty pharmacy).

Apply the Requirements/Limits shown for the specific product line (e.g., ARIKAYCE = PA, QL 28 vials/28 days, SP).

Common per‑product conditions: When a product lists PA, the prescriber must obtain prior authorization before dispensing; when QL is shown, prescriptions must not exceed the specified quantity per time period unless an exception is approved; when SP is indicated the product may require specialty pharmacy dispensing.

Examples: EPCLUSA and HARVONI show PA + QL + SP; KITABIS PAK shows PA + QL + SP.

inv-03: Formulary coverage with administrative controls

Formulary coverage requires meeting administrative controls shown on each formulary line:

Administrative coverage condition: For coverage, the drug must be dispensed within its assigned tier and meet any administrative controls listed (PA, QL, SP). Failure to meet these controls may result in denial or member financial liability.

Examples: HARVONI = PA + QL (28 tablets/28 days) + SP; MAVYRET = PA + QL (90 tablets/30 days) + SP.

Documentation requirement for PA/QL: When PA or QL is specified, the provider/pharmacy must submit supporting documentation with the prior authorization request or claims as required by the plan to demonstrate medical necessity and appropriate dosing/quantity.

See Coverage considerations and program documentation guidance for required submission processes.

inv-04: Formulary coverage entries

Each formulary entry indicates the operational rules that determine coverage and allowable supply:

Formulary entry operational rule: Every listed product line identifies Drug Tier and Requirements/Limits (examples: PA, QL, SP). Coverage is allowed only when those specified requirements are satisfied.

Examples: UPTRAVI = PA, QL 60 tablets/30 days, SP; VERQUVO = PA, QL 30 tablets/30 days; KALYDECO = PA, QL 60 tablets/30 days, SP.

Quantity limits enforce dispensing intervals: Quantity limits are expressed as maximum quantities per defined time windows (e.g., tablets per 30/28/180/365 days, mLs per 30 days); prescriptions exceeding QL require justification or exception request.

Examples drawn from formulary QL fields (e.g., sildenafil suspension QL 2 bottles/30 days; TYVASO QL specified per kit/cartridge).

The Drug List defines the scope of pharmacy coverage: drugs shown on the list are covered; drugs not shown are not covered. Coverage may be limited to FDA‑approved uses and recognized evidence‑based clinical guidelines. The document explicitly notes that non‑FDA approved drugs, repackaged medications, and certain compounded or over‑the‑counter equivalent products may be excluded from coverage. Providers should confirm coverage and any applicable utilization controls (e.g., PA, QL, SP) using the member’s plan materials or by calling the number on the member ID card.

Within the itemized formulary segments shown, some lines provide only tier assignments and do not include explicit exclusion language. That is, the extract lists product lines and their Drug Tier and Requirements/Limits fields, but it does not enumerate additional exclusion categories beyond the general exclusions noted in the coverage considerations. For specific exclusion determinations, refer to the general exclusions and the member’s benefit plan materials.

The clinical entries in these chunks focus on formulary tiering and administrative controls (e.g., PA, QL, SP). There are no explicit clinical exclusion statements

Several formulary rows show Requirements/Limits = . (blank) in the extract, indicating that no product‑specific utilization constraint (PA, QL, SP, etc.) is listed for those particular presentations in this portion of the document. Absence of a listed requirement in the extract does not guarantee lack of controls elsewhere in the full Drug List or a member’s plan—providers should verify via plan materials or the PA process.

The entries in these chunks are formulary listings with explicit requirement flags for many specialty agents but they do not include standalone clinical exclusion statements. Coverage is governed by the per‑product Requirements/Limits (for example, PA and QL flags listed next to oncology agents) rather than separate exclusion narratives in this excerpt.

In the contraceptive and hormone therapy listings shown, product lines include Drug Tier and sometimes QL or other flags, but the excerpt does not contain explicit exclusion language stating particular patients or diagnoses are excluded. Operational controls (e.g., quantity limits such as QL (30 patches/30 days)) are present where indicated.

The product listings in these chunks (including erectile dysfunction agents and cystic fibrosis or specialty pulmonary products) show tiering and utilization controls such as QL, PA, and SP. The extract does not include separate exclusion statements; therefore coverage is controlled by the listed per‑product requirements and applicable plan exclusions referenced in the general coverage considerations.

These behavioral‑health and psychotropic listings present Drug Tier and quantity limits for specific strengths/formulations (for example, lurasidone marked QL (30 tablets/30 days)). The excerpt does not provide explicit exclusion statements for these agents; coverage guidance is via the per‑line Requirements/Limits and the general exclusions described elsewhere in the Drug List.

The document specifically states that non‑FDA approved drugs are not covered and that repackaged versions of medications already available on the market are not covered. These explicit exclusions are part of the general coverage considerations and apply across the formulary unless otherwise noted.

The excerpted formulary lines and product tables do not include any explicit statements labeling listed drugs as "not medically necessary". Instead, coverage is framed by inclusion on the Drug List and adherence to utilization controls (e.g., PA, QL, SP). For NMN determinations, reviewers should consult the full policy language or medical‑necessity criteria as applicable.

Across the chunks reviewed, there is no standalone "not medically necessary" language tied to the individual product lines in the extract. The formulary emphasizes administrative controls—PA, QL, and SP—and general exclusions (e.g., non‑FDA approved or repackaged drugs) rather than NMN statements in these excerpts.

The CF and specialty product listings shown (e.g., KALYDECO, ORKAMBI, TRIKAFTA) include per‑product controls such as PA, QL, and SP but the excerpt contains no explicit NMN language for these agents. Coverage will be determined by meeting the listed utilization requirements and applicable plan exclusions.

Provider Actions, Authorization & Documentation

Prior Authorization
Prior Authorization Required
Prior Authorization (PA) may be required for many drugs listed in this Drug List. If PA is required it will be noted with 'PA' in the Requirements/Limits or Special Requirements column. Plans may require PA for additional medications beyond those shown here.
PA required for select specialty/high‑cost agents (examples include biologics, specialty injectables, inhaled aminoglycosides, CF modulators, and other high-cost therapies).
PA required for many antivirals and HCV agents (examples: EPCLUSA, HARVONI, MAVYRET — often PA + QL + SP).
PA required for many specialty/oncology agents (examples: abiraterone, alectinib, brigatinib, palbociclib, ibrutinib, trametinib, pemigatinib — typically PA + QL + SP).
PA required for multiple listed specialty products (examples include IMCIVREE, JYNARQUE, ISTURISA, GALAFOLD, REPATHA, TRIKAFTA, KALYDECO).
PA required for select antivirals/antiretrovirals and other infectious disease agents (examples: entecavir, emtricitabine, GENVOYA, PREVYMIS, ribavirin — PA/QL/SP as indicated).
PA required for certain inhaled aminoglycosides and nebulized agents (examples: ARIKAYCE, TOBI, KITABIS PAK — flagged as PA, QL, SP).
PA required for posaconazole and other antifungals where indicated.
PA required for many respiratory biologics and specialty asthma/allergy agents (examples: XOLAIR, NUCALA — often PA and SP).
PA required for weight‑management agents and select metabolic/specialty medicines (examples: MOUNJARO, OZEMPIC, WEGOVY, ZEPBOUND, SAXENDA, QSYMIA — PA and QL noted).

Documentation Required
Prior Authorization and Quantity Limits
Prior authorization and quantity limits (QL) are commonly paired for specialty/high‑cost agents. Quantity limits may restrict supply per prescription or within a timeframe (e.g., per 28 days, 30 days, 90 days).
Examples of PA + QL combinations from the Drug List: EPCLUSA (PA, QL 28 tablets/28 days, SP); HARVONI (PA, QL 28 tablets/28 days, SP); TRIKAFTA (PA, QL 56 packets/28 days, SP).
Quantity limits are displayed in Requirements/Limits (e.g., QL (4 pens/28 days), QL (60 capsules/30 days), QL (28 tablets/28 days)).
Documentation supporting PA and QL requests must be provided by the prescriber as requested by the plan (medical records, diagnosis, prior therapy trials, lab results, weight‑management indication documentation, etc.).
Failure to obtain required PA or exceed QL/SP restrictions may result in claim denial or member liability for full cost of medication.

Denial Risk
Requirement Flags, Specialty Routing & Coverage Exclusions
Special routing/designations may appear next to drugs indicating specialty pharmacy (SP), prior authorization (PA), quantity limits (QL), step therapy (ST) or access/category (AC). These flags drive provider actions and may require specialty dispensing.
PA/SP designation — many specialty products require dispensing through a specialty pharmacy (SP) and prior authorization (PA).
Requirement flags appearing in the list: PA, QL, SP, ST, AC — check the Requirements/Limits column for each drug.
Specialty program notes: SP indicates the drug is managed through the plan’s specialty program and may require specialty pharmacy fulfillment and additional documentation.
Coverage exclusions: non‑FDA approved drugs, repackaged medications, compounded medications, and drugs with OTC alternatives may be excluded — these exclusions can trigger denial if coverage criteria are not met.

Documentation Required
Documentation Required for PA and QL Requests
Documentation expectations: when PA, QL, or SP are listed, prescribers must submit required clinical documentation to support approval. This includes diagnosis, prior treatment history (when step therapy applies), relevant labs, and rationale for brand or non‑preferred product.
Required documentation elements often requested with PA/QL: medical records, prior therapy documentation, dosing schedule, treatment duration, monitoring labs, and for weight‑management drugs — BMI and prior lifestyle or pharmacologic therapy attempts.
Specialty drug documentation examples: GALAFOLD requires PA and QL with documentation of indication; IMCIVREE, JYNARQUE, ISTURISA require PA and SP with quantity limits and clinical justification.
Quantity limit documentation: when requesting amounts exceeding QL (e.g., azithromycin examples, or high‑volume nebulizers), prescribers should include rationale and supporting clinical notes.
PA/QL documentation is required for continuation and renewal requests as indicated by the plan; incomplete documentation may delay or result in denial.

Step Therapy
Step Therapy and Specialty Program Notes
Step therapy (ST) and specialty program notes appear for some agents but explicit step sequences are not listed within this excerpt. Where ST is indicated the drug row will show 'ST' in Requirements/Limits and prescribers may request an exception via the exception process.
No complete step therapy sequences are included here; the presence of 'ST' indicates a step requirement exists for that product (examples: KERENDIA shows ST; several psychiatric agents show ST for certain formulations).
Specialty program / step: SP indicates specialty management; some products with ST are also managed under specialty program rules.
If a patient has a contraindication or previous adverse reaction to first‑line therapy, prescribers may submit a step therapy exception following the exception process (decision timelines: standard 3 business days, expedited 24 hours when necessary).

Step Therapy Rules & Notes

Drug / Category	Special Requirements (flags)	Notes
General statement
Step therapy may apply to some medications
Notation: 'ST' appears under Special Requirements when step therapy is commonly required

Drug	Special Requirements	Step therapy sequence specified?
EPCLUSA (sofosbuvir-velpatasvir)
Requirements/Limits = PA, QL (28 tablets/28 days), SP
No explicit prior step or alternative required listed in excerpt

Indicator	Meaning	Implication for coverage
SP
Specialty designation (specialty pharmacy)
May require specialty program handling or step/management edits prior to coverage; explicit step edits not detailed in excerpt

Finding	Detail	Source note
Explicit step-therapy sequences
No explicit step-therapy sequences are listed in the provided chunks; document notes ST flag where applicable rather than full sequences
Refer to benefit plan materials or step therapy exception process for details

Product group	Requirements/Limits shown	Implication
Contraceptives (e.g., ANNOVERA, ARANELLE, many levonorgestrel combinations)
Requirements/Limits = AC and QL values (examples: AC, QL (1 ring/365 days); AC, QL (28 tablets/21 days))
AC indicates administrative/access category; formulary management (QL/AC) may apply prior to dispensing

Drug	Special Requirements	Step therapy flag
KERENDIA (finerenone)
Requirements/Limits = QL (30 tablets/30 days)
ST indicated on formulary line

Drug	Annotation	Coverage implication
KERENDIA (finerenone) — all strengths listed
Requirements/Limits include QL (30 tablets/30 days) and 'ST'
'ST' denotes step therapy requirement before coverage per formulary line

Product examples	Designation	Step therapy details present?
JUXTAPID, ADEMPAS, other specialty agents
Requirements/Limits = SP (and sometimes PA/QL)
SP indicates specialty channel management; specific step therapy rules are not specified in these chunks

Observation	Detail	Action
Step therapy sequences not described
Provided excerpt shows flags (PA, QL, SP, ST) but does not include step-by-step prior therapy algorithms
Consult full plan Drug List and step therapy program materials for detailed sequences

Finding	Primary controls shown	Step therapy sequences?
Formulary controls for listed products
Primary controls shown are PA and QL (e.g., XOLAIR Requirements/Limits = PA, SP; VENTOLIN HFA QL 2 inhalers/30 days)
No explicit step therapy sequences are shown in this excerpt

Drug	Requirements/Limits	Step therapy flag / coverage stance
FETZIMA (levomilnacipran) and titration pack
Requirements/Limits = ST (and QL where shown for packs)
ST indicates step therapy applies

Drug / Pack	Requirements/Limits	Step therapy flag
FANAPT (iloperidone) and FANAPT titration packs
Requirements/Limits = QL (60 tablets/30 days) for drug; titration packs QL (1 pack/180 days); Requirements/Limits include ST
ST indicates step therapy applies prior to coverage where noted

General entry	Flag meaning	Rule
Formulary entries marked 'ST'
Indicates step therapy applies to that product
Exact step therapy rules (which drugs to try first) are not provided in the excerpt

Product group	Requirements/Limits	Implication
Nicotine replacement products (gum, lozenges, patches, starter kits)
Requirements/Limits in listings include AC for several OTC-equivalent nicotine items (e.g., nicotine gum/lozenge/patch entries show AC)
AC suggests administrative/access constraints and may indicate controlled access or step edits for OTC vs covered formulations

OpenPayer

2026 Drug List (Pharmacy Benefit) - Coverage Criteria

Coverage Criteria & Formulary Rules

Formulary Listings and Coding Tables

Provider Actions, Authorization & Documentation

Step Therapy Rules & Notes

Quantity Limits by Product

Site of Care & Specialty Dispensing

Terminology & Abbreviations

Document Revision History